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Aims: We aim to assess whether a purpose-developed mobile application (app) is
non-inferior regarding effectiveness and cost-effective when used to treat women
with urinary incontinence (UI), as compared to care as usual in Dutch primary care.
Additionally, we will explore the expectations and experiences of patients and care
providers regarding app usage.
Methods: A mixed-methods study will be performed, combining a pragmatic,
randomized-controlled, non-inferiority trial with an extensive process evaluation.
Women aged ≥18 years, suffering from UI ≥ 2 times per week and with access to a
smartphone or tablet are eligible to participate. The primary outcome will be the
change in UI symptom scores at 4 months after randomization, as assessed by the
International Consultation on Incontinence Modular Questionnaire UI Short Form.
Secondary outcomeswill be the change inUI symptom scores at 12months, as well as
the patient-reported global impression of improvement, quality of life, change in
sexual functioning, UI episodes per day, and costs at 4 and 12 months. In parallel, we
will perform an extensive process evaluation to assess the expectations and
experiences of patients and care providers regarding app usage, making use of
interviews, focus group sessions, and log data analysis.
Conclusion: This study will assess both the effectiveness and cost-effectiveness of
app-based treatment for UI. The combination with the process evaluation, which will
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be performed in parallel, should also give valuable insights into the contextual factors
that influence the effectiveness of such a treatment.
KEYWORDS
eHealth, mixed methods, mobile applications, randomized controlled trial, self-management, urinary
incontinence, women
1 | BACKGROUND
eHealth, which represents health services and information
delivered or enhanced through the internet and related
technologies, is an emerging clinical resource with
potential advantages for the treatment of urinary inconti-
nence (UI).1 In particular, the use of mobile health
applications (apps) may increase adherence to treatment
advice and thereby reduce costs.2 Although conservative
treatment is effective for UI, adherence varies from 18% to
95% and is one of the main problems in the treatment of
UI.3 Also, total costs for absorbent materials, pelvic
physiotherapy, medication, and specialist care are high.4
Currently, various apps have been designed to support the
treatment of UI, but research on their effectiveness, quality,
and usability is scarce.
Recently, the use of an app-based treatment for stress UI
was assessed in Swedish women in a community setting, and
not only produced clinically relevant symptom improvement
but also reduced pad usage compared with postponed
treatment.5 In other research, an internet-based training
program was shown to be a cost-effective alternative for
treating stress UI when compared with a treatment program
sent by post.6 However, studies evaluating app-based
treatment for all three types of UI (ie, stress, urgency, and
mixed UI) are lacking, and app-based treatment for UI has
never been compared to care as usual. Moreover, there is a
lack of research into the experiences and preferences of
important stakeholders, such as patients and care providers,
which can often result in poor implementation of such eHealth
solutions.7
Therefore, using a mixed-methods study design, we will
evaluate an app-based treatment for stress, urgency, andmixed
UI in women. Our aims in this study are twofold: first, we will
assess whether a purpose-developed app is non-inferior and
cost-effective in treating women with UI, as compared to care
as usual in Dutch primary care; second, we will evaluate the
expectations and experiences of patients and care providers
regarding use of the app.By combining these results,we expect
to provide valuable insights into the facilitators of, and barriers
to favorable outcomes for mobile app use in the treatment
of UI.
2 | METHODS
2.1 | Study design
In this mixed-methods study, a pragmatic, randomized-
controlled, non-inferiority trial will be conducted in parallel
with a process evaluation study (Figure 1). The randomized-
controlled trial (RCT; Part A) is designed to study the non-
inferiority and cost-effectiveness of an app-based treatment
for UI, compared to care as usual in primary care.
We have chosen a pragmatic design because we want to
provide the best reflection of the expected effect of the
intervention under real-life conditions. We opted for non-
inferiority because we wanted to show that the intervention is
not less effective than the established treatment. This
approach is recommended in light of the fact that eHealth
interventions may offer additional advantages.8 We hypothe-
size that app-based treatment for women with incontinence
will not be less effective than care as usual in primary care,
and that it will increase the cost-effectiveness of treatment by
reducing the need for face-to-face consultations with care
providers such as general practitioners (GP) and pelvic
physiotherapists. In the process evaluation (Part B), we aim to
assess the experiences and expectations of patients and
healthcare professionals regarding the use and implementa-
tion of the new app.
The RCT is registered in the Dutch Trial Register
(registration number NTR21609), approval was obtained
from the Medical Ethical Review board of the University
Medical Center Groningen (UMCG), the Netherlands
(METc-number: 2014/574). TheMedical Research Involving
Human Subjects Act (WMO) does not apply for the process
evaluation, which has been confirmed by the Medical Ethical
Review board of the UMCG (letter-number: M17.207954).
2.2 | Part A: The RCT
2.2.1 | Setting
Participants will be recruited in the northern part of the
Netherlands. Recruitment has started in October 2015
through primary care practices. Additionally, as from
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November 2017, participants are also recruited through lay
press and social media attention and through the study
website.
2.2.2 | Recruitment of participants
The process for participant recruitment is shown in Figure 2.
We will use the following inclusion criteria: female sex; age
≥18 years; self-reported stress, urgency, or mixed UI at least
twice a week according to the Three Incontinence Questions
(3IQ, Appendix 2); wanting treatment; and access to a
smartphone or tablet. Women are excluded in case of:
indwelling urinary catheter, urogenital malignancy, previous
surgery for UI, treatment for UI in the previous year
(pharmacological or non-pharmacological), terminal or
serious illness, cognitive impairment, or psychiatric illness,
urinary tract infection (UTI) (dipstick, and if negative,
dipslide or urine culture), overflow or continuous UI,
pregnancy or recent childbirth (<6 months ago) or the
inability to complete a questionnaire in Dutch. Eligibility is
assessed by the patient's GP or by the research physician
based on a patient history. As from November 2017,
urinalyses will only be performed in case of clinical suspicion
of a UTI. Eligible womenwill be invited to participate with an
information letter. Informed consent will be obtained by the
researcher during baseline assessment.
2.2.3 | Randomization
After baseline assessment the researcher will randomize the
participants using the validated web-based computer program
ALEA.9 Block randomization with random block sizes will be
applied at the GP level to correct for differences between GPs.
2.2.4 | Interventions
The URinControl App
Participants in the intervention group will have access to a
smartphone or tablet app, which we named the URinControl
App. This contains a step-by-step program for the treatment
of each type of UI, mainly focusing on pelvic floor muscle
and/or bladder training depending on the primary diagnosis
(Appendix 1, Figure 3). The app will guide participants to the
FIGURE 1 An overview of the mixed-methods for the URinControl study design. Part A shows the RCT with details of the planned baseline
assessment and follow-up assessments at 4 and 12 months. Part B shows the planned process evaluation that will be conducted parallel to the
RCT, and that will collect app usage data, patient feedback, patient interviews, focus group sessions and a questionnaire for care providers.
Results from the usability study with patients and the focus group sessions will be used to develop a quantitative questionnaire and form an
interview guide for a qualitative evaluation within the RCT
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appropriate part of the app, to start directed training, and, if
applicable, when to add the other type of training. Participants
in the intervention armwill be asked to use the application as a
self-management tool without caregiver involvement. The
research team will only provide technical support, but the
participant will be free to contact her GP regarding any
questions regarding the medical aspects of her condition or
treatment. The GP can then decide what additional support is
needed, if any.
Care as usual (control group)
Participants in the control group will receive treatment
according to the Dutch GP guideline on UI.10 They will be
referred back to their GP who will discuss the various
treatment options. The management plan can then vary
depending on the preferences of patients and GPs, but may
involve any of the following: instructions on pelvic floor
muscle and/or bladder training; prescribing a pessary, drugs,
or absorbent products; or referral to a continence nurse, a
FIGURE 2 Flowchart of patient inclusion and assessments in the randomized-controlled trial (Part A). GP, general practitioner; UI, urinary
incontinence
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pelvic physiotherapist, or to secondary care (ie, a urologist/
gynecologist). Due to the pragmatic nature of this trial,
referred patients will be treated according to current guide-
lines in these settings. Detailed information on the applied
treatments will be collected.
2.3 | Measurements
2.3.1 | Baseline assessment
History and physical examination
After gaining informed consent, a research physician will
assess age, parity, UI duration, comorbidity, and drug use, and
will measure the participant's weight and height, and perform
a baseline urogynecological assessment. Pelvic floor muscle
function will be assessed according to recommendations of
the International Continence Society, and the stage of pelvic
organ prolapse will be assessed using the Pelvic Organ
Prolapse Quantification (POP-Q) method.11,12
Questionnaires
Participants will complete validated questionnaires on UI
symptoms (the International Consultation on Incontinence
Modular Questionnaire UI Short Form, ICIQ-UI-SF); condi-
tion-specific (ICIQ-LUTS-QoL) and generic health-related
(EuroQol questionnaire, EQ-5D-5L) quality of life; and the
influence of incontinence on sexuality (Pelvic Organ Prolapse/
Incontinence Sexual Questionnaire, International Urogyneco-
logical Association-revised: PISQ-IR). Finally, a question on
the use of absorbent pads and UI-specific healthcare will be
added to the questionnaire set (Appendix 2).
Frequency volume chart
Participants will complete a three-day frequency volume
chart that will be used to gain insight into the frequency of
micturition, number of UI episodes, and volumes of urine
voided per micturition.
2.3.2 | Follow-up assessment
At 4 and 12 months, all baseline questionnaires will be
repeated. Participants will also complete a frequency chart
(without volume measurements). Additionally, the Patient
Global Impression of Improvement (PGI-I), for both
incontinence and sexuality, will be administered. All medical
cost items related to UI will be measured with the adjusted
versions of the Institute of Medical Technology Assessment
FIGURE 3 A schematic representation of the contents of the URinControl App. (A) Information on both types of urinary incontinence,
prevention and treatment options, as well as information on anatomy and function of the pelvic floor. (B) Training programs for both stress and
urgency urinary incontinence (pelvic floor muscle training and bladder training, respectively). (C) Functionalities of the App, including three
reminder-options, the graph function, and a patient feedback option
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Medical Consumption Questionnaire (iMTA-MCQ) and the
Productivity Costs Questionnaire (iMTA-PCQ). After
12 months, data from the electronic medical records of GPs
will be collected retrospectively to assess UI-specific costs,
including that related to referrals, consultations with health-
care professionals, prescribedmedication and absorbent pads,
and UI-associated comorbidity.
2.3.3 | App usage
Wewill monitor App usage by two types of data; data filled in
by the participant and automatically logged data. Participants
are invited to fill in whether they performed their exercises, at
what level and if it went well. Actual activity is automatically
logged; for example, data on opening/closing different
exercise levels and duration of use.
2.3.4 | Primary outcome
The primary outcome of interest is the change in UI
symptoms score assessed by the ICIQ-UI-SF at 4 months
after randomization.
2.3.5 | Secondary outcomes
The secondary outcomes are as follows:
 Severity of UI (measured with the ICIQ-UI-SF) at
12 months.
 Patient's global impression of improvement (PGI-I) on UI
and sexuality at 4 and 12 months.
 Condition-specific quality of life (assessed with the ICIQ-
LUTS-QoL) at 4 and 12 months.
 Generic health-related quality of life (assessed with the
EQ5D-5L) at 4 and 12 months.
 Condition-specific sexual functioning (assessed with the
PISQ-IR) at 4 and 12 months.
 Number of UI episodes per day (derived from frequency
charts) at 4 and 12 months.
 Costs at 4 and 12 months, measured with the adjusted
iMTA-MCQ and iMTA-PCQ, and extracted from elec-
tronic medical records after 12 months.
2.3.6 | Blinding
Due to the nature of the interventions, blinding for treatment
allocation is not feasible.
2.3.7 | Sample size
We have opted for a non-inferiority design, which means
that the sample size calculation is based on the hypothesis
that the app-based treatment group will be inferior to the
care as usual group (H0 hypothesis). Rejection of this
hypothesis leads to acceptance of non-inferiority (H1
hypothesis). One recent study, using anchor-based methods
to determine the minimal clinically important difference
(MCID), identified a between-treatment MCID of 1.58
points among patients with stress UI.13 We therefore based
the sample size calculation on an estimated non-inferiority
margin of 1.5 points, a one-sided type I error of 0.025, and a
power of 0.80. This generated a total requirement of 100
evaluable patients per group. Allowing for an expected loss-
to-follow-up of up to 20%, we will require 250 patients for
this study. We aim to have 90 participating GP's, who
should include 2,5 patients each. We expect this to be
achievable, since the incidence of UI in primary practice is
9.3 per 1000 patient years.14
2.3.8 | Analysis
Descriptive analyses
Wewill describe frequencies of stress, urgency, andmixed UI
for the intervention and control groups, including analysis by
age distribution, educational level, previous smartphone and/
or tablet experience, recruitment strategy, and baseline
questionnaire scores.
Analyses of clinical outcomes
A linear regression model will be used for non-inferiority
testing, with adjustment for confounders if necessary. In case
of non-inferiority, we will assess superiority with a two-sided
test, using a significance level of P< 0.05. A missing value
analysis will be performed and multiple imputation techni-
ques will be used, as appropriate.
There is no gold-standard analysis in non-inferiority
trials. Intention-to-treat (ITT) analyses, risk bias toward the
null hypothesis.15 However, the alternative per-protocol (PP)
analysis can cause bias in either direction by allowing patients
to be excluded.15 Therefore, both ITT and PP analyses will be
performed in this study.
Analysis of cost data
In the economic evaluation, the primary aim will be to
estimate the societal costs of women with UI using an
interactive app compared with the costs of care as usual
following established guidance. Such a societal perspective
incorporates direct and indirect healthcare costs, such as
direct medical costs, patient and family costs, and costs due to
productivity losses.16
A cost-effectiveness analysis (CEA) will also be
performed from a societal perspective. We will use the
incremental cost-effectiveness ratio (ICER) as a composite
outcome score. The ICER will indicate the ratio of additional
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costs or gains of treatment based on using the app, as well as
the additional change in symptom score measured with the
ICIQ-UI-SF, compared to care as usual. We will also perform
a cost-utility analysis based on EuroQol 5D-5L defined
utilities.17
2.4 | Part B: Process Evaluation
Process evaluations can improve the validity and outcome
interpretation of RCTs to help refine an intervention.18 We
therefore aim to conduct an extensive process evaluation to
answer two research questions:
1. What are the experiences and expectations of patients and
care providers regarding the use and implementation of our
app-based management of UI?
2. What is associated with success or failure of the app-based
management of UI?
To answer the first research question, we will conduct a
usability study. To avoid influencing the RCT, we will recruit
women who meet the inclusion criteria, but who do not
participate in the RCT. Participants will be asked to use the
URinControl App for 6 weeks, after which semi-structured
interviewswill be conducted to assess usability preferences and
experiences. Additionally, focus group sessions will be held
with relevant occupational groups (eg, GPs, practice assistants,
pelvic physical therapists, and urogynecologists) and supple-
mentedwith onemultidisciplinary focus group session. Results
from the usability studywill be used to provide additional input
for these sessions. Focus group sessions will be exploratory in
nature, so participants with a range of characteristics will be
invited from local health facilities. Finally, the results from the
usability study and focus group sessionswill be used to develop
a quantitative questionnaire that will be distributed among
health professionals in the Netherlands to assess their opinions
on the themes collected. This should provide a deeper
understanding of the context in which future implementation
of an app for UI should take place.
To answer the second research question, we will integrate
the results of automatically logged usage data (log data)
analysis, patient interviews, and quantitative results of the
RCT. Log data will be gathered from the apps to provide a
more in-depth insight into adherence.19 After 12 months’
follow-up, patient interviews will be held, aiming to include
approximately 40 participants from the RCT. The results from
the previously described focus group sessions and usability
study will be used to form an interview guide for this
qualitative evaluation within the RCT. Additionally, during
the RCT, participants will be asked to answer open-ended
questions at baseline and follow-up regarding their personal
view on the success or failure of treatment. By integrating
these results with quantitative results of the RCT, we aim to
provide greater insight into the facilitators of, and barriers to,
treatment success with the URinControl App.
2.5 | Analysis
The semi-structured interviews and focus group sessions will
be recorded using a digital voice recorder and transcribed
verbatim. Transcriptions will be coded using the Atlas.ti
(Scientific Software Development program). Coding will be
performed separately by two researchers and checked for
agreement. Data analysis will be driven by an inductive
approach, allowing themes to emerge from the data by
constant comparison.
2.6 | Sample size
Participants will continue to be enrolled for individual
interviews until no new themes emerge from the data (ie,
saturation is reached).20 The focus groups will be performed
with care providers and consist of 6-8 people per session.
3 | DISCUSSION
This study will evaluate an app-based treatment of UI for
women in primary care, using a mixed-methods design. The
non-inferiority to care as usual, the cost-effectiveness, and the
expectations and experiences of stakeholders will be
evaluated. Ultimately, the study aims to provide more insight
into the processes underlying the use and effectiveness of an
app for managing UI, which should help to improve the
development and implementation of this and future eHealth
tools.
To the best of our knowledge this is the first proposal that
seeks to evaluate an eHealth-treatment for stress, urgency,
and mixed UI, and it is the first that aims to do so in a help-
seeking population in primary care. Only two previous studies
have assessed internet- and/or app-based treatment for stress
UI. These studies differ from ours in terms of treatment
comparison (either a group receiving postal information or a
group receiving postponed treatment, rather than comparison
to usual care).5,6
The main strength of this study will be in the
combination of research methods used. A mixed-methods
study design is frequently used in social science and can
make an important contribution to RCTs evaluating health
service interventions.21 In our design, the quality of the
process evaluation has been strengthened by applying the
three methods described by Zhang et al, namely the
integration of quantitative with qualitative data, connecting
portions of the study in phases, and embedding a parallel
conducted qualitative assessment alongside an RCT.22
Other strengths are the use of a non-inferiority design,
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the evaluation of experiences of both patients and
professionals throughout the process, the societal cost-
effectiveness evaluation, and the use of log data analyses.
The use of pragmatic effectiveness analyses will provide a
realistic comparison between care as usual and app-based
treatment, and the use of log data from the app will provide
valuable information on actual app use, progress, and
adherence. Together, this information is essential to
anticipate whether implementation will improve healthcare
outcomes.
Potential challenges lie in participant recruitment, notably
because there are well-known barriers to women seeking help
for UI.23 Another possible limitation may lie in the use of a
pragmatic design; indeed, the features that support the
generalizability of the results to real-world practice may also
limit the interpretation of the results.24 These features include
the lack of blinding and possible sub-optimal adherence to
therapy. Research within eHealth is relatively young, and
there is no gold-standard process for conducting a process
evaluation in this field.
We believe that this study is unique in combining several
current guidelines on study design with advice regarding
process evaluation, both in general and within eHealth
specifically.7,18,25 Therefore, this study design offers a
multifaceted evaluation of an app-based eHealth intervention.
4 | FUTURE PERSPECTIVES
Although eHealth is a promising and emerging technology,
urogynecology apps have not been adequately tested or
compared to care as usual. Moreover, experiences and
preferences of important stakeholders are often not explored,
resulting in poor implementation.7 The results of this study
will provide valuable insights into the contextual factors that
influence the effectiveness of a mobile app in the treatment of
UI and will provide useful information for the development
and evaluation of future eHealth applications. If successful,
the URinControl App will be made openly available for
patients and health professionals, providing an easily
accessible treatment option for women who experience
barriers to asking for care.
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APPENDIX 1
URinControl App: contents and development
Main objectives
The program content is a translation of the recommenda-
tions of the guidelines on the treatment of female UI in
primary care.10 Development of the URinControl App was
based on the following objectives: 1) to inform and educate
the patient about UI; 2) to guide the patient through the
main treatment exercises, without the need of instruction
from a healthcare professional; 3) to increase adherence to
exercises by integrating them in daily life; and 4) to give
the patient insight into treatment progress (number and
level of exercises performed over time). An overview of
the contents of the URinControl App is shown in Figure 3.
Development and technical information
Members of the research project and its advisors, including
physicians, pelvic physiotherapists, and patients, collabo-
rated to develop the URinControl App program. The
eHealth developers are experienced in the development of
internet-based medical programs, and the program has been
built on a secure platform, using a Secure Sockets Layer.
During the study, the app will be exclusively available on
the iOS™ (version 8.1) and Android™ (version 2.3.3)
platforms through Therapieland B.V. (version 1.30 and 1.3),
for patients in the intervention group. A pilot study was
performed with patients suffering from UI to detect any
irregularities and to review user-friendliness. Security and
user-friendliness were also reviewed and approved by the




The International Consultation on Incontinence Modular
Questionnaire Urinary Incontinence Short Form (ICIQ-UI-
SF): This is a self-completed questionnaire that measures
frequency, volume, and impact on daily life of involuntary
urine loss. Scores range from 0 to 21, with higher scores
correlating with worse incontinence. This questionnaire
measures patient-reported outcomes in UI and is recom-
mended by the International Consultation on Incontinence.
The Three Incontinence Questions (3IQ): This is a simple
and quick questionnaire with acceptable accuracy for
classifying urge and stress incontinence, appropriate for use
in primary care. The questions correspond with the three
questions recommended in the Dutch guideline on UI for
assessing the type of incontinence (ie, stress UI, urgency UI,
and mixed UI).
Condition-specific quality of life (ICIQ-LUTS-QoL): a
psychometrically robust patient-completed questionnaire
evaluating quality of life in patients with UI, which is used
in research and clinical practice worldwide. It has received a
Grade A recommendation from the International Continence
Society for use in women with UI. The overall score ranges
from 19 to 76.
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Generic Health-related Quality of Life (EQ-5D-5L): This
is a commonly used measurement of general health status, with
good validity and reliability reported in various health conditions.
Health states, as defined by the five-dimensional descriptive
system of this questionnaire, will be converted into a weighted
health state index, using the EuroQol crosswalk value set.
Patient-reported Global Impression of Improvement
(PGI-I): This is a single item index, measured on a seven-
point Likert scale (verymuch better, much better, a little better,
no change, a little worse, much worse, very much worse)
Pelvic Organ Prolapse/Incontinence Sexual Question-
naire, International Urogynecological Association-revised
(PISQ-IR): This is the only instrument validated in both
sexually active and sexually inactive women with pelvic floor
dysfunction.
The Institute of Medical Technology Assessment-Medical
Consumption Questionnaire and iMTA Productivity Costs
Questionnaire (iMTA-MCQ and iMTA-PCQ): The adjusted
versions of these questionnaires are used tomeasure the use of
healthcare and non-healthcare resources.
10 | LOOHUIS ET AL.
